OBIGEN Pharma Showcases Progress of Taiwan’s Only Independently Developed Botulinum Toxin Product at BIO Asia–Taiwan 2025

OBIGEN Pharma Approved by the Ministry of Economic Affairs as a Biotechnology and Pharmaceutical Company

OBIGEN Pharma Biologics Board Approves Execution of Term Sheet for China Licensing of Novel Botulinum Toxin OBI-858

New Botulinum Toxin Product OBI-858 Planned to Enter Phase II Clinical Trial